Administration of high‐dose interleukin‐2 in a 2‐year‐old with metastatic melanoma | Zendy

Bernhardt M. Brooke | Zendy; Hicks M. John | Zendy; Pappo Alberto S. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Administration of high‐dose interleukin‐2 in a 2‐year‐old with metastatic melanoma

Author(s) -

Bernhardt M. Brooke,

Hicks M. John,

Pappo Alberto S.

Publication year - 2009

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.22255

Subject(s) - medicine , metastatic melanoma , blood cancer , melanoma , interleukin 2 , disease , oncology , metastasis , cancer , pediatrics , cancer research , cytokine

Malignant melanoma is rare in pediatrics, and therapies for patients with disseminated disease have not been well studied. This report describes our experience with the use of high‐dose interleukin 2 (aldesleukin, IL‐2) in a 2‐year‐old child with metastatic melanoma and describes our approach for the administration of this agent to young patients. Pediatr Blood Cancer 2009; 53:1346–1348. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research